DENGUE


    MD.KABIUL AKHTER ALI
        Vector Borne Disease Consultant
                        NVBDCP, NRHM
  District Heath & Family Welfare Samiti
                           Uttar Dinajpur
Distribution
   Endemic in more than
    100 tropical and
    subtropical countries
   Pandemic began in South
    East Asia after WW II
    with subsequent global
    spread
   Several epidemics since
    1980s
   Distribution is comparable
    to malaria
Epidemiology

In India first outbreak of dengue was recorded in
1812

A double peak hemorrhagic fever epidemic
occurred in India for the first time in Calcutta
between July 1963 & March 1964

In New Delhi, outbreaks of dengue fever reported
in 1967,1970,1982, &1996
Burden of disease in S.E. Asia
CATEGORY-A
(INDONESIA,MYANMAR & THAILAND)

CATEGORY-B
(INDIA,BANGALADESH,MALDIVES & SRILANKA)

CATEGORY-C
(BHUTAN, NEPAL)

CTEGORY-D
(DPR KOREA)
Dengue Endemic Areas
(1996 to 2010 = 29 States/UTs)
                        Risk factors:
                        •Construction
                        activities

                        • Water         storage
                        practice

                        •Population
                        movement

                        •Heavy rainfall

                        •Vector abundance
Dengue ppt
Dengue Fever
   Dengue endemic in 29 States/UTs, upsurge observed in 2010
   States reported higher numbers of cases in 2010 (as on Dec 31)




   Dengue being reported from newer areas (Assam, Meghalaya,
    Chhattisgarh, Jharkhand, Manipur, Nagaland, Uttarakhand ,A&N
    Islands)
Dengue ppt
Dengue ppt
WHAT IS DENDUE ?
•Dengue is a viral disease

•It is transmitted by the infective bite of female Aedes Aegypti mosquito

•Man develops disease after 5-6 days of being bitten by an infective
mosquito

•It occurs in two forms: Dengue Fever and Dengue Haemorrhagic
Fever(DHF)

•Dengue Fever is a severe, flu-like illness (Influenza)

•Dengue Haemorrhagic Fever (DHF) is a more severe form of
disease, which may cause death

•Person suspected of having dengue fever or DHF must see a doctor at once
Dengue clinical syndrome
There are actually      four   dengue   clinical
  syndromes:

1. Undifferentiated fever;

2. Classic dengue fever;

3. Dengue hemorrhagic fever, or DHF; and

4. Dengue shock syndrome, or DSS.

Dengue shock syndrome is actually a severe
 form of DHF.
CLASSIS DENGUE
   Acute febrile illness with headache, retro-orbital
    pain, myalgia, arthralgia
   “Break-bone fever”
   High fever 5-7 days
   Second fever for 1-2 days in 5% patients
   Followed by marked fatigue days to weeks
   Classic dengue 15-60% of infections
   Nausea, vomiting, diarrhea (30%)
   Macular or maculopapular rash (50%)
   Respiratory symptoms: cough, sore throat (30%)
SIGNS & SYMPTOMS OF DENGUE FEVER

•Abrupt onset of high fever

•Severe frontal headache

•Pain behind the eyes which worsens with eye movement

•Muscle and joint pains

•Loss of sense of taste and appetite

•Measles-like rash over chest and upper limbs

•Nausea and vomiting
Dengue Hemorrhagic Fever
WHO classification of DHF              Usually occurs in secondary
                                       infections after actively or passively
   Thrombocytopenia (platelet count   (maternal) acquired immunity to a
    <100,000)                          different viral serotype

                                       Only 2-4% of secondary infections
   Fever 2-7 days                     result in severe disease

 Hemorrhagic manifestations with a    Mortality is 10-20% if untreated,
  positive tourniquet test             but decreases to <1% if adequately
 Hemoconcentration or evidence of     treated
  plasma leakage
                                       Plasma leakage may progress to
                                       dengue shock syndrome
SIGNS & SYMPTOMS OF DENGUE
HAEMORRHAGIC FEVER AND SHOCK SYNDROM
• Symptoms similar to dengue fever

•Severe continuous stomach pains

•Skin becomes pale, cold or clammy

•Bleeding from nose, mouth & gums and skin rashes

•Frequent vomiting with or without blood

•Sleepiness and restlessness

•Patient feels thirsty and mouth becomes dry

•Rapid weak pulse

•Difficulty in breathing
AGENT FACTORS
•The dengue viruses are the members of the genus
flavivirus. These small (50nm)viruses contain single stranded
RNA.

•There are four virus serotypes, which are designated as
DEN-1, DEN-2, DEN-3 and DEN-4.

•Although all four serotypes are antigenicaly similar, they
are different enough to elicit cross-protection only for a few
months after infection by any one of them. Infection with
any one serotype confers lifelong immunity to the virus
serotype.

•Man and mosquito are reservoirs of infection. Transovarian
transmission (infection carried over to next progeny of
mosquitoes through eggs) has made the control more
complicated.

•At present DEN1 and DEN2 serotypes are widespread in
India
VECTOR OF DENGUE
• Dengue is transmitted by the bite of female Aedes mosquito


• In India Ae. aegypti is the main vector in most urban areas; however,
   Ae albopictus is also found as vector in few areas of southern India.
• Female Aedes mosquito deposits eggs singly on damp surfaces just
above the water line. Under optimal conditions the life cycle of aquatic
stage of Ae. Aegypti (the time taken from hatching to adult
emergence) can be as short as seven days
• The eggs can survive one year without water. At low temperature,
however, it may take several weeks to emerge. Ae. aegypti has an
average adult survival of fifteen days. During the rainy season, when
survival is longer, the risk of virus transmission is greater. It is a day time
feeder and can fly up to a limited distance of 400 meters. To get one full
blood meal the mosquito has to feed on several persons, infecting all of
them.
TRANSMISSION CYCLE OF DENGUE




##There is evidence that vertical transmission of dengue virus from infected
female mosquitoes to the next generation occurs through eggs, which is known as
transovarian transmission.
TRANSMISSION CYCLE OF DENGUE
1.The virus is inoculated into humans with the
mosquito saliva.

2.The virus localizes and replicates in various target
organs, for example, local lymph nodes and the
liver.

3.The virus is then released from these tissues and
spreads through the blood to infect white blood
cells and other lymphatic tissues.

4.The virus is then released from these tissues and
circulates in the blood.

5.The mosquito ingests blood containing the virus.

6.The virus replicates in the mosquito midgut, the
ovaries, nerve tissue and fat body. It then escapes
into the body cavity, and later infects the salivary
glands.

7.The virus replicates in the salivary glands and
when the mosquito bites another human, the cycle
continues.
Few common and favoured
breeding places/sites of
Ae. aegypti
LABORATORY DIAGNOSIS OF DENGUE

   Haemagglutination inhibition (HI) test

    Compliment Fixation Test (CFT)

        Neutralization test (NT)

  IgM-capture Enzyme-Linked Immunosorbent
   Assay (MAC-ELISA) ndvbcp recommended

               IgG-ELISA

         Rapid Diagnostic tests (NS 1)
Management of Dengue Fever (DF)
• No specific therapy, management of Dengue fever is symptomatic and
supportive
i. Bed rest is advisable during the acute phase.
ii. Use cold sponging to keep temperature below 39o C.
iii. Antipyretics may be used to lower the body temperature. Aspirin/NSAID like
Ibuprofen etc should be avoided since it may cause gastritis, vomiting, acidosis
and platelet disfunction.
Paracetamol is preferable in the doses as follows:
1-2 years: 60 -120 mg/doses 3-6 years: 120 mg/dose 7-12 years: 240 mg/dose
Adult : 500mg/dose
In children the dose is calculated as per 10mg/KG Body Weight per dose
which can be repeated at the interval of 6hrs
iv. Oral fluid and electrolyte therapy are recommended for patients with
excessive sweating or vomiting.
v. Patients should be monitored in DHF endemic area until they become
afebrile for one day without the use of antipyretics and after platelet and
haematocrit determinations are stable, platelet count is >50,000/ cumm.
Vaccination
   No current dengue vaccine
   Estimated availability in 5-10 years
   Vaccine development is problematic as the vaccine
    must provide immunity to all 4 serotypes
   Lack of dengue animal model
   Live attenuated tetravalent vaccines under phase 2
    trials
   New approaches include infectious clone DNA and
    naked DNA vaccines
Prevention
Personal:
 clothing to reduce exposed skin
 insect repellent especially in early morning, late
  afternoon. Bed netting important
 mosquito repellants(pyrethroid based)
 coils, sanitation measures

Environmental:
 reduced vector breeding sites
 solid waste management
 public education
 empty water containers and cut weed/tall grass
Prevention
Biological:
 Target larval stage of Aedes in large water storage
  containers
 Larvivorous fish (Gambusia), endotoxin producing
  bacteria (Bacillus), copepod crustaceans (mesocyclops)
Chemical:
Thermal fogging-malathion,pyrethrum
 Insecticide treatment of water containers
 Space spraying (thermal fogs)
 Indoor space spraying(2% pyrethrum),
  organophosphorus compounds
Social Issues
Although the goal of disease control is to prevent epidemic
transmission, if an epidemic does occur, ways to minimize its
impact include:

•Teaching the medical community how to diagnose and manage
dengue and dengue hemorrhagic fever (DHF), so they are better
prepared to effectively manage and treat large numbers of cases.
Mortality from DHF will thus be minimized.

•Implementing an emergency contingency plan to anticipate the
logistical issues of hospitalizing large numbers of patients and to
outline measures for community-wide vector control activities.
Such plans should be prepared with the participation of all parties
and agencies involved, and should be ready for implementation
prior to the emergence of an epidemic.

•Educating the general public to encourage and enable them to
carry out vector control in their homes and neighborhoods.
Dengue ppt
Dengue ppt
Dengue ppt
Dengue ppt
Dengue ppt
Public Health
   Major and escalating global public health problem

   Global demographic changes: urbanization and population
    growth with substandard housing, water, and waster
    management systems

   Deteriorating public health infrastructure with limited
    resources resulting in “crisis management” not prevention

   Increased travel

   Lack of effective mosquito control
Initiatives
 Strategic action plan
 Guidelines on clinical management
 13 centers identified for Apex Referral laboratories for
  diagnosis/treatment and surveillance
ICMR Virus Unit, Kolkata.
 137 sentinel surveillance hospitals amongst them in west
  bengal
 1.Burdwan Medical College Hospital.
 2. School of Tropical Medicine, Calcutta
 NIV Pune to supply ELISA kits
 Contingency grant made available
 IEC/BCC
THANK YOU

More Related Content

PPTX
Dengue fever ppt
PPT
The geological time scale
PPTX
Control of communicable diseases
PPT
Geological Time Scale
PPTX
Approach to thrombocytopenia.pptx
PPTX
Determinants of health
PPTX
Thyroid & antithyroid drugs
PDF
Guidelines On The Prevention of Dengue fever
Dengue fever ppt
The geological time scale
Control of communicable diseases
Geological Time Scale
Approach to thrombocytopenia.pptx
Determinants of health
Thyroid & antithyroid drugs
Guidelines On The Prevention of Dengue fever

What's hot (20)

PPTX
PDF
Smallpox
PPT
Dengue
PPTX
Epidemiology and control of filariasis (Lymphatic Filariasis) in India
PPTX
Dengue fever
PPTX
Chikungunya
PPT
Chicken pox
PPTX
Dengue fever presentation
PPTX
Covid19 corona virus
PPTX
HIV/AIDS Management
PPT
Hepatitis A
PPTX
Chicken pox
PPTX
Malaria ppt.
PPT
Dengue Fever
PPT
dengue
PPTX
TYPHOID FEVER
PPT
Mumps ppt biju
PPT
Swine flu ppt
PPTX
Influenza
Smallpox
Dengue
Epidemiology and control of filariasis (Lymphatic Filariasis) in India
Dengue fever
Chikungunya
Chicken pox
Dengue fever presentation
Covid19 corona virus
HIV/AIDS Management
Hepatitis A
Chicken pox
Malaria ppt.
Dengue Fever
dengue
TYPHOID FEVER
Mumps ppt biju
Swine flu ppt
Influenza
Ad

Viewers also liked (16)

PPT
Dengue Fever Power Point
PPT
Surgical Infections
DOCX
pro chikunguniya
PPT
Dengue with who guidelines
PPTX
Dengue fever slide
PPTX
Virus chikungunya 
PPT
DENGUE FEVER
PPTX
Chikungunya
PPT
Surgical infections
PPTX
Chikungunya
PPTX
Chikungunya fever
PPTX
PPT
Accerlerated hypertension
PPTX
Dengue ppt
PPTX
chronic kidney disease.ppt
PPT
Chronic Kidney Disease
Dengue Fever Power Point
Surgical Infections
pro chikunguniya
Dengue with who guidelines
Dengue fever slide
Virus chikungunya 
DENGUE FEVER
Chikungunya
Surgical infections
Chikungunya
Chikungunya fever
Accerlerated hypertension
Dengue ppt
chronic kidney disease.ppt
Chronic Kidney Disease
Ad

Similar to Dengue ppt (20)

PPT
Dengue
PPT
Dengue
PPT
Dengue and chikungunia disease class .ppt
PPTX
dengue.pptx
PPTX
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
PPTX
PPTX
Dengue & chikungunea prevention.ppt .pptx
PPTX
Dengue & chikungunea prevention.ppt .pptx
PPTX
PPTX
Dengue.pptx
PDF
Dengue epidemiology
PPTX
VIRAL HEMORRHAGIC FEVERS INTERNAL MEDICINE
PPTX
PPSX
PPTX
PPTX
Dengue illnesses praman
PPTX
DENGUE Fever and other symptoms of dengue fever
PPT
Dengue Fever.ppt
DOCX
denguedenguedenguedenguedenguedengue.docx
PPTX
Dengue fever
Dengue
Dengue
Dengue and chikungunia disease class .ppt
dengue.pptx
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue & chikungunea prevention.ppt .pptx
Dengue & chikungunea prevention.ppt .pptx
Dengue.pptx
Dengue epidemiology
VIRAL HEMORRHAGIC FEVERS INTERNAL MEDICINE
Dengue illnesses praman
DENGUE Fever and other symptoms of dengue fever
Dengue Fever.ppt
denguedenguedenguedenguedenguedengue.docx
Dengue fever

More from Md Kabiul Akhter Ali (8)

PDF
World health day 2014
PPTX
Anti dengue month , July 2013
PPTX
Anti malaria month june 2013
PPT
Pip 2013-2014
PPT
Kala azar & malaria,uttar dinajpur.ppt
PPT
Kala azar presentation in bengali
World health day 2014
Anti dengue month , July 2013
Anti malaria month june 2013
Pip 2013-2014
Kala azar & malaria,uttar dinajpur.ppt
Kala azar presentation in bengali

Recently uploaded (20)

PPTX
Introduction to CDC (1).pptx for health science students
PPTX
Approach to chest pain, SOB, palpitation and prolonged fever
PPTX
Biostatistics Lecture Notes_Dadason.pptx
PPTX
DIARRHOEA IN CHILDREN presented to COG.ppt
PPTX
Congenital Anomalies of Eyelids and Orbit
PPTX
Tuberculosis : NTEP and recent updates (2024)
PPT
fiscal planning in nursing and administration
PDF
New-Child for VP Shunt Placement – Anaesthetic Management - Copy (1).pdf
PDF
Muscular System Educational Presentation in Blue Yellow Pink handdrawn style...
PPTX
Pharynx and larynx -4.............pptx
PDF
Tackling Intensified Climatic Civil and Meteorological Aviation Weather Chall...
PDF
Geriatrics Chapter 1 powerpoint for PA-S
PPTX
approach to chest pain dr. Omar shahid ppt
PPTX
Hypertensive disorders in pregnancy.pptx
PDF
MNEMONICS MNEMONICS MNEMONICS MNEMONICS s
PPTX
etomidate and ketamine action mechanism.pptx
PPTX
Critical Issues in Periodontal Research- An overview
PDF
Strategies-S3-Hyperglycemic-Emergencies.021017.pdf
PDF
NCM-107-LEC-REVIEWER.pdf 555555555555555
PPTX
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha
Introduction to CDC (1).pptx for health science students
Approach to chest pain, SOB, palpitation and prolonged fever
Biostatistics Lecture Notes_Dadason.pptx
DIARRHOEA IN CHILDREN presented to COG.ppt
Congenital Anomalies of Eyelids and Orbit
Tuberculosis : NTEP and recent updates (2024)
fiscal planning in nursing and administration
New-Child for VP Shunt Placement – Anaesthetic Management - Copy (1).pdf
Muscular System Educational Presentation in Blue Yellow Pink handdrawn style...
Pharynx and larynx -4.............pptx
Tackling Intensified Climatic Civil and Meteorological Aviation Weather Chall...
Geriatrics Chapter 1 powerpoint for PA-S
approach to chest pain dr. Omar shahid ppt
Hypertensive disorders in pregnancy.pptx
MNEMONICS MNEMONICS MNEMONICS MNEMONICS s
etomidate and ketamine action mechanism.pptx
Critical Issues in Periodontal Research- An overview
Strategies-S3-Hyperglycemic-Emergencies.021017.pdf
NCM-107-LEC-REVIEWER.pdf 555555555555555
NUCLEAR-MEDICINE-Copy.pptxbabaabahahahaahha

Dengue ppt

  • 1. DENGUE MD.KABIUL AKHTER ALI Vector Borne Disease Consultant NVBDCP, NRHM District Heath & Family Welfare Samiti Uttar Dinajpur
  • 2. Distribution  Endemic in more than 100 tropical and subtropical countries  Pandemic began in South East Asia after WW II with subsequent global spread  Several epidemics since 1980s  Distribution is comparable to malaria
  • 3. Epidemiology In India first outbreak of dengue was recorded in 1812 A double peak hemorrhagic fever epidemic occurred in India for the first time in Calcutta between July 1963 & March 1964 In New Delhi, outbreaks of dengue fever reported in 1967,1970,1982, &1996
  • 4. Burden of disease in S.E. Asia CATEGORY-A (INDONESIA,MYANMAR & THAILAND) CATEGORY-B (INDIA,BANGALADESH,MALDIVES & SRILANKA) CATEGORY-C (BHUTAN, NEPAL) CTEGORY-D (DPR KOREA)
  • 5. Dengue Endemic Areas (1996 to 2010 = 29 States/UTs) Risk factors: •Construction activities • Water storage practice •Population movement •Heavy rainfall •Vector abundance
  • 7. Dengue Fever  Dengue endemic in 29 States/UTs, upsurge observed in 2010  States reported higher numbers of cases in 2010 (as on Dec 31)  Dengue being reported from newer areas (Assam, Meghalaya, Chhattisgarh, Jharkhand, Manipur, Nagaland, Uttarakhand ,A&N Islands)
  • 10. WHAT IS DENDUE ? •Dengue is a viral disease •It is transmitted by the infective bite of female Aedes Aegypti mosquito •Man develops disease after 5-6 days of being bitten by an infective mosquito •It occurs in two forms: Dengue Fever and Dengue Haemorrhagic Fever(DHF) •Dengue Fever is a severe, flu-like illness (Influenza) •Dengue Haemorrhagic Fever (DHF) is a more severe form of disease, which may cause death •Person suspected of having dengue fever or DHF must see a doctor at once
  • 11. Dengue clinical syndrome There are actually four dengue clinical syndromes: 1. Undifferentiated fever; 2. Classic dengue fever; 3. Dengue hemorrhagic fever, or DHF; and 4. Dengue shock syndrome, or DSS. Dengue shock syndrome is actually a severe form of DHF.
  • 12. CLASSIS DENGUE  Acute febrile illness with headache, retro-orbital pain, myalgia, arthralgia  “Break-bone fever”  High fever 5-7 days  Second fever for 1-2 days in 5% patients  Followed by marked fatigue days to weeks  Classic dengue 15-60% of infections  Nausea, vomiting, diarrhea (30%)  Macular or maculopapular rash (50%)  Respiratory symptoms: cough, sore throat (30%)
  • 13. SIGNS & SYMPTOMS OF DENGUE FEVER •Abrupt onset of high fever •Severe frontal headache •Pain behind the eyes which worsens with eye movement •Muscle and joint pains •Loss of sense of taste and appetite •Measles-like rash over chest and upper limbs •Nausea and vomiting
  • 14. Dengue Hemorrhagic Fever WHO classification of DHF Usually occurs in secondary infections after actively or passively  Thrombocytopenia (platelet count (maternal) acquired immunity to a <100,000) different viral serotype Only 2-4% of secondary infections  Fever 2-7 days result in severe disease  Hemorrhagic manifestations with a Mortality is 10-20% if untreated, positive tourniquet test but decreases to <1% if adequately  Hemoconcentration or evidence of treated plasma leakage Plasma leakage may progress to dengue shock syndrome
  • 15. SIGNS & SYMPTOMS OF DENGUE HAEMORRHAGIC FEVER AND SHOCK SYNDROM • Symptoms similar to dengue fever •Severe continuous stomach pains •Skin becomes pale, cold or clammy •Bleeding from nose, mouth & gums and skin rashes •Frequent vomiting with or without blood •Sleepiness and restlessness •Patient feels thirsty and mouth becomes dry •Rapid weak pulse •Difficulty in breathing
  • 16. AGENT FACTORS •The dengue viruses are the members of the genus flavivirus. These small (50nm)viruses contain single stranded RNA. •There are four virus serotypes, which are designated as DEN-1, DEN-2, DEN-3 and DEN-4. •Although all four serotypes are antigenicaly similar, they are different enough to elicit cross-protection only for a few months after infection by any one of them. Infection with any one serotype confers lifelong immunity to the virus serotype. •Man and mosquito are reservoirs of infection. Transovarian transmission (infection carried over to next progeny of mosquitoes through eggs) has made the control more complicated. •At present DEN1 and DEN2 serotypes are widespread in India
  • 17. VECTOR OF DENGUE • Dengue is transmitted by the bite of female Aedes mosquito • In India Ae. aegypti is the main vector in most urban areas; however, Ae albopictus is also found as vector in few areas of southern India. • Female Aedes mosquito deposits eggs singly on damp surfaces just above the water line. Under optimal conditions the life cycle of aquatic stage of Ae. Aegypti (the time taken from hatching to adult emergence) can be as short as seven days • The eggs can survive one year without water. At low temperature, however, it may take several weeks to emerge. Ae. aegypti has an average adult survival of fifteen days. During the rainy season, when survival is longer, the risk of virus transmission is greater. It is a day time feeder and can fly up to a limited distance of 400 meters. To get one full blood meal the mosquito has to feed on several persons, infecting all of them.
  • 18. TRANSMISSION CYCLE OF DENGUE ##There is evidence that vertical transmission of dengue virus from infected female mosquitoes to the next generation occurs through eggs, which is known as transovarian transmission.
  • 19. TRANSMISSION CYCLE OF DENGUE 1.The virus is inoculated into humans with the mosquito saliva. 2.The virus localizes and replicates in various target organs, for example, local lymph nodes and the liver. 3.The virus is then released from these tissues and spreads through the blood to infect white blood cells and other lymphatic tissues. 4.The virus is then released from these tissues and circulates in the blood. 5.The mosquito ingests blood containing the virus. 6.The virus replicates in the mosquito midgut, the ovaries, nerve tissue and fat body. It then escapes into the body cavity, and later infects the salivary glands. 7.The virus replicates in the salivary glands and when the mosquito bites another human, the cycle continues.
  • 20. Few common and favoured breeding places/sites of Ae. aegypti
  • 21. LABORATORY DIAGNOSIS OF DENGUE Haemagglutination inhibition (HI) test Compliment Fixation Test (CFT) Neutralization test (NT) IgM-capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA) ndvbcp recommended IgG-ELISA Rapid Diagnostic tests (NS 1)
  • 22. Management of Dengue Fever (DF) • No specific therapy, management of Dengue fever is symptomatic and supportive i. Bed rest is advisable during the acute phase. ii. Use cold sponging to keep temperature below 39o C. iii. Antipyretics may be used to lower the body temperature. Aspirin/NSAID like Ibuprofen etc should be avoided since it may cause gastritis, vomiting, acidosis and platelet disfunction. Paracetamol is preferable in the doses as follows: 1-2 years: 60 -120 mg/doses 3-6 years: 120 mg/dose 7-12 years: 240 mg/dose Adult : 500mg/dose In children the dose is calculated as per 10mg/KG Body Weight per dose which can be repeated at the interval of 6hrs iv. Oral fluid and electrolyte therapy are recommended for patients with excessive sweating or vomiting. v. Patients should be monitored in DHF endemic area until they become afebrile for one day without the use of antipyretics and after platelet and haematocrit determinations are stable, platelet count is >50,000/ cumm.
  • 23. Vaccination  No current dengue vaccine  Estimated availability in 5-10 years  Vaccine development is problematic as the vaccine must provide immunity to all 4 serotypes  Lack of dengue animal model  Live attenuated tetravalent vaccines under phase 2 trials  New approaches include infectious clone DNA and naked DNA vaccines
  • 24. Prevention Personal:  clothing to reduce exposed skin  insect repellent especially in early morning, late afternoon. Bed netting important  mosquito repellants(pyrethroid based)  coils, sanitation measures Environmental:  reduced vector breeding sites  solid waste management  public education  empty water containers and cut weed/tall grass
  • 25. Prevention Biological:  Target larval stage of Aedes in large water storage containers  Larvivorous fish (Gambusia), endotoxin producing bacteria (Bacillus), copepod crustaceans (mesocyclops) Chemical: Thermal fogging-malathion,pyrethrum  Insecticide treatment of water containers  Space spraying (thermal fogs)  Indoor space spraying(2% pyrethrum), organophosphorus compounds
  • 26. Social Issues Although the goal of disease control is to prevent epidemic transmission, if an epidemic does occur, ways to minimize its impact include: •Teaching the medical community how to diagnose and manage dengue and dengue hemorrhagic fever (DHF), so they are better prepared to effectively manage and treat large numbers of cases. Mortality from DHF will thus be minimized. •Implementing an emergency contingency plan to anticipate the logistical issues of hospitalizing large numbers of patients and to outline measures for community-wide vector control activities. Such plans should be prepared with the participation of all parties and agencies involved, and should be ready for implementation prior to the emergence of an epidemic. •Educating the general public to encourage and enable them to carry out vector control in their homes and neighborhoods.
  • 32. Public Health  Major and escalating global public health problem  Global demographic changes: urbanization and population growth with substandard housing, water, and waster management systems  Deteriorating public health infrastructure with limited resources resulting in “crisis management” not prevention  Increased travel  Lack of effective mosquito control
  • 33. Initiatives  Strategic action plan  Guidelines on clinical management  13 centers identified for Apex Referral laboratories for diagnosis/treatment and surveillance ICMR Virus Unit, Kolkata.  137 sentinel surveillance hospitals amongst them in west bengal  1.Burdwan Medical College Hospital.  2. School of Tropical Medicine, Calcutta  NIV Pune to supply ELISA kits  Contingency grant made available  IEC/BCC